Clinical studies with dopamine-receptor stimulants
- Cite this article as:
- Angrist, B., Thompson, H., Shopsin, B. et al. Psychopharmacologia (1975) 44: 273. doi:10.1007/BF00428906
- 36 Downloads
Oral administration of ET-495 was found to cause worsening of psychiatric status in 4 out of 7 schizophrenic patients, and to induce a paranoid state and a syndrome of auditory hallucinosis in 2 non-schizophrenics. These observations were compatible with the hypothesized role of dopamine in schizophrenia. However, these psychotogenic effects were far less dramatic than those noted in other studies with amphetamine, methylphenidate or l-Dopa. Possible explanations for this differing psychotogenic potency of receptor stimulators versus presynaptic agonists are presented. Intravenous ET-495 and apomorphine did not show psychotogenic effects.
Key wordsSchizophrenia Dopamine ET 495 Apomorphine Clinical studies
Unable to display preview. Download preview PDF.